Inhibiting the type 2 inflammatory pathway with dupilumab is associated with an increase in interleukin‐4 and interleukin‐18 production

Saved in:
Bibliographic Details
Published inInternational forum of allergy & rhinology Vol. 12; no. 10; pp. 1313 - 1316
Main Authors Morris, Jymirah, Olonisakin, Tolani F., Moore, John A., Phan, BaDoi, Parker, Dana M., Uribe, Bliss A., Barel, Stephanie J., Bowers, Eve M.R., Buchheit, Kathleen M., Laidlaw, Tanya M., Lee, Stella E.
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.10.2022
Subjects
chronic rhinosinusitis
cytokine
dupilumab
Inflammation
Monoclonal antibodies
nasal polyposis
Rhinitis
Sinusitis
type 2 inflammation
cytokine
chronic rhinosinusitis
type 2 inflammation
nasal polyposis
dupilumab
Online AccessGet full text

Cover

More Information
Bibliography:Jymirah Morris and Tolani F. Olonisakin contributed equally to this work.
Potential conflict of interest: S.E.L.: clinical trial funding from Sanofi Aventis Regeneron, GlaxoSmithKline, AstraZeneca, and OptiNose, and participated on advisory boards for GlaxoSmithKline, AstraZeneca, Sanofi Aventis, Regeneron, Genentech, and Novartis; J.A.M: clinical trial salary support from Sanofi Aventis Regeneron, GlaxoSmithKline, AstraZeneca, Genentech, and Optinose; T.M.L: research funding from Regeneron and GlaxoSmithKline, and participated on advisory boards for Sanofi‐Aventis Regeneron, GlaxoSmithKline, and AstraZeneca.
View this article online at wileyonlinelibrary.com.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2042-6976
2042-6984
DOI:10.1002/alr.23003